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Background: General anesthesia usually requires mechanical ventilation, which is traditionally accomplished with
constant tidal volumes in volume- or pressure-controlled modes. Experimental studies suggest that the use of
variable tidal volumes (variable ventilation) recruits lung tissue, improves pulmonary function and reduces systemic
inflammatory response. However, it is currently not known whether patients undergoing open abdominal surgery
might benefit from intraoperative variable ventilation.
Methods/Design: The PROtective VARiable ventilation trial (‘PROVAR’) is a single center, randomized controlled trial
enrolling 50 patients who are planning for open abdominal surgery expected to last longer than 3 hours. PROVAR
compares conventional (non-variable) lung protective ventilation (CV) with variable lung protective ventilation (VV)
regarding pulmonary function and inflammatory response. The primary endpoint of the study is the forced vital
capacity on the first postoperative day. Secondary endpoints include further lung function tests, plasma cytokine
levels, spatial distribution of ventilation assessed by means of electrical impedance tomography and postoperative
pulmonary complications.
Discussion: We hypothesize that VV improves lung function and reduces systemic inflammatory response
compared to CV in patients receiving mechanical ventilation during general anesthesia for open abdominal surgery
longer than 3 hours. PROVAR is the first randomized controlled trial aiming at intra- and postoperative effects of
VV on lung function. This study may help to define the role of VV during general anesthesia requiring mechanical
ventilation.
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General anesthesia promotes pulmonary atelectasis [1] and
this effect is further enhanced during open abdominal sur-
gery [2], mainly due to the use of muscle paralysis. Indeed,
with relaxation of the diaphragm, the intra-abdominal
pressure is transmitted to the intrathoracic cavity, promot-
ing compression of the lung parenchyma and resulting in
more atelectasis. Atelectasis and the decrease in pulmon-
ary gas volume can persist during the postoperative period.
It has been shown that forced vital capacity (FVC) and
other variables of lung function are reduced for up to three
hours postoperatively compared to pre-operative values
[3]. It has been shown that noninfectious pulmonary com-
plications like atelectasis or pleural effusions may favor the
development of pneumonia [4], and increased bacterial
translocation has been found from atelectatic lung regions
[5]. The presence of atelectasis may promote the deve-
lopment of ventilator-associated lung injury due to cyclic
collapse and re-opening of atelectatic lung regions [6].
Consequently, atelectasis formation is associated with in-
creased length of stay in the recovery room and also with
increased admission to the intensive care unit [7,8].
The application of positive end-expiratory airway pres-
sure (PEEP) combined with lung recruitment maneuvers
has been shown to reduce atelectasis and improve lung
function [9,10]. However, recruitment maneuvers and high
levels of PEEP carry the risk of barotrauma and deterior-
ation of hemodynamics, and do not represent standard of
practice in general anesthesia.
Recent data suggest that variable ventilation may im-
prove lung function without causing structural damage to
the lungs or increasing pulmonary inflammatory response
in the experimental [11] and clinical setting [12]. One
important mode of action of variable ventilation is the re-
cruitment of previously collapsed lung areas. Variable ven-
tilation is not only able to induce lung recruitment [13],
but also to keep alveoli open once they are recruited [14].
This mechanism is of special importance in the presence
of low or moderate settings of positive end-expiratory
pressure, as planned in the presented trial. Variable ventila-
tion mimics some aspects of the physiological ventilation
pattern of healthy, spontaneously breathing individuals,
but so far it is not known if variable ventilation is able to
improve postoperative pulmonary function and reduce sys-
temic pro-inflammatory response after surgery.
Recently, it has been demonstrated that a lung protective
ventilation approach for general anesthesia can improve
lung function and decrease postoperative pulmonary
complications after open abdominal surgery [9]. The
PROtective VARiable ventilation trial (‘PROVAR’) compares
conventional (non-variable) lung protective ventilation
(CV) and variable lung protective ventilation (VV) regard-
ing pulmonary function and systemic inflammatory re-
sponse. We hypothesized that VV improves lung function,redistributes ventilation toward gravity-dependent lung
areas and reduces systemic inflammatory response com-
pared to CV during controlled mechanical ventilation
without spontaneous breathing activity in patients planned
for open abdominal surgery expected to be longer than
3 hours.
Methods/Design
Objectives and design
PROVAR is an investigator-initiated, single center, ran-
domized controlled, two-arm trial comparing CV and
VV in patients receiving mechanical ventilation during
general anesthesia for open abdominal surgery.
The study protocol is approved by the institutional re-
view board of the Medical Faculty and the University
Hospital Dresden, Germany (EK 174052011) and has
been registered at clinicaltrials.gov (NCT01683578).
PROVAR is conducted in accordance with the Declar-
ation of Helsinki and the principles of good clinical
practice.
PROVAR tests the hypothesis that intraoperative VV
is associated with improved pulmonary function and re-
duced systemic inflammatory response compared to CV
in patients planned for open abdominal surgery. Primary
endpoint is the FVC on the first postoperative day. Sec-
ondary endpoints are plasma concentrations of interleukin
(IL)-6, IL-8 and tumor necrosis factor alpha (TNF-α);
partial pressure of oxygen in capillary blood (PcO2) on
the first postoperative day; peak expiratory flow (PEF) on
the first postoperative day; forced expiratory volume in
the first second (FEV1) on the first postoperative day; oxy-
genation (PaO2/FIO2) during surgery; changes of spatial
distribution of ventilation measured by electrical imped-
ance tomography (EIT); amount of atelectasis measured
with magnetic resonance imaging (MRI) on the first post-
operative day; and occurrence of postoperative pulmonary
complications defined by the modified clinical pulmonary
infection score (mCPIS) [9]. Figure 1 shows the CONSORT
diagram of PROVAR.
Screening, enrollment, randomization and blinding
Investigators screen consecutive patients planned for
open abdominal surgery with an expected duration >3 h
at the University Hospital Dresden, Germany during
regular anesthesiological preoperative evaluations. The
screening started in September 2012, and a recruitment
time of 24 months has been defined based on the inci-
dence of major abdominal surgery and patient charac-
teristics at our hospital. Demographic data of screened
patients are recorded regardless of whether they meet
the enrollment criteria. Informed consent is obtained
from all patients prior to surgery. All screened patients
are reviewed with respect to inclusion and exclusion cri-
teria as summarized in Table 1.
Figure 1 CONSORT diagram for the PROVAR trial. VT, tidal
volume; CV VT, coefficient of variation of tidal volume.
Table 1 Inclusion and exclusion criteria for the PROVAR trial
Inclusion Exclusion
Patients scheduled for elective open abdominal surgery
with expected duration >3 h
Chronic lung dis
ASA class 2 and 3 Body mass index
Expected extubation in the OR Hypersensitivity
against drugs w
Informed consent to participate in the study signed by
the patient
Participation of t
History of substa
consent
Pregnancy or br
Women in an ag
• Postmenopaus
FSH >40 lU/ml)
• Postoperative (
• Regular and co
• Sexual inactivit
• Vasectomy of s
Suspected low p
Contraindication
Mechanical vent
ASA, American Society of Anesthesiologists; OR, operating room; COPD, chronic obs
disease; FSH, follicle-stimulating hormone; MRI, magnetic resonance imaging.
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mization with fixed 1:1 randomization ratios within blocks
of 2 × 10, 3 × 6 and 3 × 4 patients using closed envelopes.
Blinding is achieved by means of a modified triple blind
design with the patients and postoperative investigators
blinded to the treatment and the intraoperative investiga-
tor blinded to the pre- and postoperative measurements.
Intervention
After randomization, patients will be ventilated either with
CV or VV, respectively. Both modes are performed with
the same ventilator (EVITA XL4Lab, Dräger Medical,
Lübeck, Germany) in a volume-controlled mode with
a fraction of inspired oxygen (FIO2) of 0.35, PEEP of 5
cmH2O, tidal volumes (VT) of 8 ml/kg and an I:E ratio of
1:1. Respiratory rate is adjusted to achieve normocapnia
(4.6 to 6.0 kPa). While VT is kept constant during CV, it
varies randomly on a breath-by-breath basis during VV. In
VV, the mean VT is kept at 8 ml/kg, and the distribution
of values follows a Gaussian distribution with coefficient
of variation at 30%, as described by our group in detail
elsewhere [11]. Such mechanical ventilation mode is ac-
complished by computer remote control of the ventilator,
which is allowed by the manufacturer for clinical use.
Table 2 shows the ventilator settings. In case of desatur-
ation (SpO2 < 94% for more than one minute) a standard-
ized rescue maneuver is implemented in the protocol.
After exclusion of nonventilatory causes, the followingease, except COPD GOLD stage I and II and untreated bronchial asthma
>40
or allergy against one of the drugs administered during the study or
ith similar chemical structure
he patient in another clinical trial within the last 4 weeks
nce abuse or any other mental status possibly affecting informed
eastfeeding
e range of possible pregnancy if not:
al (12 months of amenorrhea or 6 months of amenorrheawith serum
6 weeks after bilateral ovariectomy with or without hysterectomy)
rrect use of contraceptives with failure rate of <1% per year
y
exual partner
atient compliance
for MRI exams
ilation within the last 30 days
tructive pulmonary disease; GOLD, global initiative for chronic obstructive lung
Table 2 Intraoperative ventilator settings for the PROVAR trial
Conventional ventilation Variable ventilation
FIO2 0.35 0.35
PEEP 5 cmH2O 5 cmH2O
VT 8 ml/kg Mean value of 8 ml/kg, breath by breath variability with a CV VT of 30%
RR Adjusted according normocapnia (4.6-6.0 kPa) Adjusted according normocapnia (4.6 to 6.0 kPa)
I:E 1:1 1:1
Flow 30 L/min, adjusted in case of flow limitation 30 L/min, adjusted in case of flow limitation
Pmax 40 cmH2O 40 cmH2O
FIO2, fraction of inspired oxygen; PEEP, positive end-expiratory pressure; VT, tidal volume; RR, respiratory rate; I:E, ratio of inspiratory to expiratory time; Flow, air
flow; Pmax, maximum of inspiratory pressure; CV VT, coefficient of variation of tidal volume.
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wise increase of FIO2 in steps of 10% up to 100%; 2) a
stepwise increase of PEEP in steps of 1 cmH2O up to
12 cmH2O; and 3) a recruitment maneuver with Paw 40
cmH2O for 20s. In case of malfunction or technical prob-
lems with the remote computer control during VV, the
computer will be disconnected and the ventilator will be
switched back to CV. In case of any ventilatory or other
medical problems, interventions will be performed based
on the discretion of the anesthesiologist in charge of the
patient according to clinical standards and will be docu-
mented in the case report form accordingly.
Time course of interventions/study protocol
At day 0 (visit 1), informed consent is obtained, demo-
graphic data are recorded and spirometry, EIT measure-
ments and capillary blood gas analysis performed to
retrieve baseline data. Additionally, potentially fertile fe-
male patients are submitted to a pregnancy test.
Visit 2 is performed on the day of surgery. A preoperative
MRI of the lungs is performed prior to premedication.
Preparation for anesthesia and surgery is done according to
standard of care. Anesthesia induction and maintenance
is standardized according to the following protocol: all
weight-derived calculations are based on ideal body weight
defined as 50 or 45.5 (male or female, respectively) + 0.91*
(height - 152.4): Anesthesia induction is performed with
continuous infusion of 0.5 μg/kg/h remifentanil and a bolus
of 1 to 2 mg/kg propofol. Neuromuscular blockade to fa-
cilitate endotracheal intubation is achieved by bolus ad-
ministration of 0.2 mg/kg cisatracurium. Maintenance of
anesthesia is monitored by bispectral index (BIS level 40
to 60) and is achieved by continuous infusion of 5 mg/kg/h
propofol, 0.2 to 0.3 μg/kg/h remifentanil and 0.09 mg/kg/h
cisatracurium. Neuromuscular blockade is checked hourly
by muscle relaxometry using the train of four ratio aiming
at values of 0 to 1. During induction of anesthesia, an
electrolyte solution is administered at a rate of 500 ml/h
and reduced thereafter to a maintenance rate of 300 ml/h.
Noradrenaline can be infused if necessary to ensure mean
arterial blood pressure levels >60 mmHg. After inductionand prior to the start of surgery, postinduction mea-
surements are performed and patients are then ran-
domly assigned to mechanical ventilation with CV or VV.
EIT measurements and blood plasma samples are ob-
tained postinduction, as well as after surgical wound clos-
ure (postclosure) before the end of anesthesia. Arterial
blood gases are measured hourly throughout surgery and
hemodynamics, as well as spirometric data, are recorded
from the monitoring system and the ventilator, respect-
ively. Amounts of infused drugs and fluids, as well as
blood loss and urine output, are recorded. Visit 3 takes
place on the first postoperative day. Spirometry, lung MRI,
EIT, plasma blood sampling and capillary gasometry are
performed, and adverse, as well as severe adverse, events
(AEs, SAEs) are recorded.
Visit 4 is performed on the third postoperative day.
Spirometry, EIT, plasma blood sampling and capillary
gasometry are obtained, and AEs and SAEs recorded.
Visit 5 takes place on the fifth postoperative day and
includes spirometry, EIT, plasma blood sampling and ca-
pillary gasometry. AEs and SAEs will be recorded.
Visit 6 represents the final examination before hospital
discharge. Spirometry, EIT, plasma blood sampling and
capillary gasometry will be measured, and AEs and SAEs
will be recorded.
Technical aspects
For electrical impedance tomography (EIT), a Pulmo-
Vista® 500 (Dräger Medical, Lübeck, Germany) will be
used. Files will be acquired over 2 min, with a frame rate
of 20 Frames/s. Distribution of ventilation across the
ventral-dorsal gradient will be determined from relative
changes in electrical impedance as described elsewhere
[15]. Briefly, images of the EIT device containing 32 ×
32 pixels will be recorded at a rate of 20 frames/s during
2 min for offline analysis. Using a dedicated routine
(EITa!), the highest and lowest limits of the area contain-
ing changes in the impedance (region of interest (ROI))
will be determined. The ROI will be divided into three
zones with equal heights (ventral, central and dorsal)
and the relative changes in impedance will be computed.
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preoperatively and at the first postoperative day. Native MRI
sequences using T2 (HASTE: TR/TE = 1000 ms/98 ms;
360 ms per slice) and T1 (VIBE: TR/TE = 5 ms/2 ms; 12 s
per volume × 2) will be obtained during inspiratory breath
hold. A radiologist blinded to the study groups will manu-
ally measure thickness of atelectasis and pleural effusions.
Volumetric measurements of aerated and nonaerated lung
tissue will be performed using manual segmentation and
volumetric measurements using the OsiriX software
package.Study dropouts
Participation in the trial is voluntary. A subject has the
right to withdraw from the study at any time for any rea-
son without any consequences for further medical treat-
ment. Furthermore, both investigators, intraoperative as
well as postoperative, have the right to terminate the
participation of any subject at any time during the part
of the study they are responsible for if the investigator
deems it in the participant’s best interest. The reasons
and circumstances for study discontinuation will be doc-
umented in the Case Report Form (CRF). All data are
analyzed based on the intention-to-treat (ITT) principle.Statistics
Sample size calculation was based on a previous study
using FVC as a measure of postoperative pulmonary func-
tion following general anesthesia [3]. In the present study,
effect size was estimated as 1.086, alpha was defined as 0.05
and power as 0.95. Using a two-tailed Mann–Whitney-U-
test, sample size calculation yielded 25 patients per group.
Analysis was performed using GPower (Software Version
3.1.3, University of Düsseldorf, Germany).
Exploratory analysis will include mean and standard devi-
ation for normally distributed variables. Non-normally dis-
tributed variables will be expressed by their medians and
interquartile ranges. Categorical variables will be expressed
as n (%). Parametrical or non-parametrical tests will be
used as appropriate to analyze the data. P values for
multiple comparisons will be adjusted according to the
Bonferroni procedure.
In case of loss to follow-up or consent withdrawal from
the trial, the causes will be reported. ITT and per protocol
(PP) analysis will be conducted. For the intention-to-treat
analysis, data will be processed for all trial patients in the
groups in which they were randomized. The PP analysis
will be performed as a secondary analysis if there are a
considerable number of patients who do not receive study
therapy or are lost to outcome assessment. Missing data
will be handled by means of the last observation carried
forward method.Study organization
All serious adverse events and all unexpected and related
or possibly related adverse events will be reported to the
internal review board of the Medical Faculty and the
University Hospital Dresden. Regular checks for plausibil-
ity and protocol adherence will be done according to good
clinical practice (GCP) guidelines. Two independent ex-
perts in the field that are not part of the study group serve
on the study’s data safety and monitoring board (DSMB)
to ensure adherence to the study protocol, quality of data
collection and processing as well as safety issues related to
the study.Discussion
The concept of VV has been extensively studied in recent
years. A growing body of experimental evidence suggests
the beneficial effects of variable ventilatory modes mim-
icking physiological variability of the respiratory system
[11,13,16,17]. After the introduction of variable pressure-
support ventilation (noisy PSV) by our group in 2008 [18],
we could demonstrate that the beneficial effects of VV are
not only limited to controlled mechanical ventilation but
can also be applied during assisted spontaneous breathing
[15,19]. Comparing biological variable ventilation and ran-
dom (noisy) variability using equal amounts of variability,
it has been demonstrated that both respiratory patterns
yielded comparable effects on lung function. The authors
conclude that the amount, but not the pattern, of respira-
tory variability is crucial for the success of VV [20]. It is
worth noting that the variability administered during VV
in this study is closely related to the physiological variabil-
ity of the respiratory system [11,21,22] and has been found
to be superior to higher or lower levels of variability in
previous experimental studies [23].
Several mechanisms have been proposed to explain the
beneficial effects of VV: 1) the de novo synthesis of sur-
factant proteins seems to be enhanced during VV [24,25];
2) VV seems to recruit previously closed alveolar units
[14,26]; 3) the concept of stochastic resonance may ex-
plain improvements in respiratory mechanics [17]; and
4) the beneficial effects on gas exchange may be explained
by improved ventilation/perfusion matching [18,27].
In the only clinical trial performed with VV in patients
undergoing general surgery so far, Boker and colleagues
could demonstrate that biological variable ventilation im-
proves gas exchange and respiratory mechanics compared
to CV in patients undergoing abdominal aortic aneurysm
repair [12]. Their results were confirmed by a small pilot
study in eight critically ill patients [28]. The PROVAR
study aims at closing the gap between preclinical data and
initial clinical application by providing new insights into
the perioperative physiological changes due to different
intraoperative mechanical ventilation modalities.
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to be addressed:
1. The duration of mechanical ventilation may be
different across patients due to different lengths of
surgery.
2. As part of the clinical routine some patients will
receive thoracic epidural anesthesia, whereas others
who have contraindications will not; therefore,
thoracic epidural anesthesia will be implemented as
a covariate in the statistical analysis.
3. Generalizability of the study results is critical since
until today there is no commercially available
ventilator or anesthesia machine able to perform VV.
4. The anesthesiologist in charge of the intraoperative
part of the study cannot be blinded to the ventilator
mode; we therefore decided to split personnel for
intra- and perioperative analysis in order to have at
least the perioperative staff blinded to the ventilator
mode.
In conclusion, PROVAR is the first randomized con-
trolled trial aiming at intra- and postoperative effects of
VV on lung function. This study may help to define the
role of VV during general anesthesia requiring mechan-
ical ventilation.
Trial status
Enrollment has begun.
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